| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$153 |
3Q 2024 Trading Update & Strategic Review
|
31 Oct 2024 8:23AM |
$0.515 |
$0.350 |
fallen by
32.04%
|
|
FDV - Price-sensitive ASX Announcement
Full Release
Key Points
- FDV reported A$83.4m revenue for the last twelve months to 3Q 2024, a 5% increase.
- EBITDA for the same period reached A$7.2m, showing a 14% rise.
- The 360 LATAM segment generated A$55.4m in revenue, a 12% increase.
- A strategic review has been initiated to maximize shareholder value focused on 360 LATAM.
- The current market valuation does not reflect the value of FDV's operating regions.
- FDV's revenue has shifted significantly to Latin America, with 66% of total revenue coming from there.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| G8 Education Limited (GEM) ORDINARY FULLY PAID |
Consumer Discretionary |
$729 |
Update - Notification of buy-back - GEM
|
31 Oct 2024 8:22AM |
$1.320 |
$0.945 |
fallen by
28.41%
|
|
| Altair Minerals Limited (ALR) ORDINARY FULLY PAID |
Materials |
$34 |
ALR September 2024 Quarterly Activities Report & Appendix 5B
|
31 Oct 2024 8:22AM |
$0.004 |
$0.008 |
risen by
128.57%
|
|
ALR - Price-sensitive ASX Announcement
Full Release
Key Points
- Assay results from Wee MacGregor project showed 18 samples over 1% copper and 9 samples over 1g/t gold.
- Surface sampling indicated exceptional grades of near surface copper and gold at Wee MacGregor.
- The Horse-Well Project is strategically located near BHP’s Oak Dam West discovery.
- Geophysical data from the Olympic Domain project is being reprocessed to identify new targets.
- Altair is evaluating opportunities in the resources sector and aims to generate value for shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alcidion Group Limited (ALC) ORDINARY FULLY PAID |
Health Care |
$148 |
Q1 FY25 Quarterly Activities Report and Appendix 4C
|
31 Oct 2024 8:22AM |
$0.052 |
$0.110 |
risen by
111.54%
|
|
ALC - Price-sensitive ASX Announcement
Full Release
Key Points
- New TCV sales of $5.2 million in Q1 FY25.
- Five-year contract signed with Hume Rural Health Alliance valued at $4.0 million.
- Expected revenue recognition of $2.0 million in FY25.
- Cash receipts of $6.3 million and operating cash outflow of $3.9 million.
- Targeting EBITDA positive for FY25 with breakeven revenue of approximately $36.0 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bio-Gene Technology Ltd (BGT) ORDINARY FULLY PAID |
Materials |
$7 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:22AM |
$0.058 |
$0.022 |
fallen by
62.07%
|
|
BGT - Price-sensitive ASX Announcement
Full Release
Key Points
- Collaboration with Envu to evaluate Flavocide for mosquito management.
- Successful pilot-scale production of Flavocide by Rallis India.
- Regulatory studies for Flavocide registration confirmed.
- Cash reserves decreased to $1.4 million.
- Plans for commercial-scale production post-regulatory approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Many Peaks Minerals Limited (MPK) ORDINARY FULLY PAID |
Materials |
$87 |
Quarterly Activities Report & Appendix 5B
|
31 Oct 2024 8:21AM |
$0.235 |
$0.703 |
risen by
198.94%
|
|
MPK - Price-sensitive ASX Announcement
Full Release
Key Points
- 5,000m air core drilling campaign targeting high-strain corridor at Odienné project.
- 8,810m of reconnaissance drilling at Odienné successfully delineated >16km of priority targets.
- Fully funded exploration campaigns through CY2025 with AU$6.8M cash at hand.
- Major acquisitions completed for four gold projects in Côte d'Ivoire totaling 1,919km2.
- Ferké gold project exploration work planned following successful auger drilling results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$55 |
Update - Notification of buy-back - BOL
|
31 Oct 2024 8:21AM |
$0.145 |
$1.340 |
risen by
824.14%
|
|
| Rimfire Pacific Mining Limited (RIM) ORDINARY FULLY PAID |
Materials |
$35 |
Investor Presentation - October 2024
|
31 Oct 2024 8:21AM |
$0.060 |
$0.013 |
fallen by
78.15%
|
|
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$88 |
Annual Report to Shareholders FY2024
|
31 Oct 2024 8:21AM |
$0.505 |
$0.375 |
fallen by
25.74%
|
|
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$14 |
Field Work Campaigns to Begin at Antimony Prospects
|
31 Oct 2024 8:21AM |
$0.008 |
$0.005 |
fallen by
37.50%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Field work campaigns to commence at Hillgrove South and Mayview prospects.
- Desktop studies confirmed historic antimony occurrences in the Halls Peak Project.
- Geological mapping and sampling programs will delineate drilling targets.
- The Mayview prospect is potentially a continuation of the Hillgrove Antimony-Gold system.
- Elevated antimony values recorded in stream sediment samples south of Hillgrove.
- Experienced geologists will conduct detailed surveys of historic antimony workings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coventry Group Limited (CYG) ORDINARY FULLY PAID |
Industrials |
$82 |
Appointment of new Director - Rob Martino
|
31 Oct 2024 8:21AM |
$1.380 |
$0.685 |
fallen by
50.36%
|
|
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$379 |
Share Purchase Plan - Letter to Shareholders and Booklet
|
31 Oct 2024 8:21AM |
$0.260 |
$0.160 |
fallen by
38.46%
|
|
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$88 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:21AM |
$0.505 |
$0.375 |
fallen by
25.74%
|
|
M7T - Price-sensitive ASX Announcement
Full Release
Key Points
- Mach7 Technologies Limited focuses on strategic investments to enhance product innovation and customer service.
- CARR was reported at A$27.5M as of 30 September 2024.
- The company aims for 15-25% growth in CARR and revenue in FY25.
- Mach7 holds cash reserves of A$21.9M with plans to be cash flow positive in FY25.
- Sales orders for Q1 FY25 amounted to A$2.2M, primarily from ARR-type sales.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Adherium Limited (ADR) ORDINARY FULLY PAID |
Health Care |
$7 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:20AM |
$0.014 |
$0.004 |
fallen by
71.43%
|
|
ADR - Price-sensitive ASX Announcement
Full Release
Key Points
- Adherium is on track to onboard over 600 patients by next quarter.
- Strong sales pipeline of over 50 healthcare organizations.
- Pursuing opportunities in new revenue segment – Pharmacy Benefit Management.
- Strategic investment in customer and patient journey process to facilitate continued growth.
- CEO Dr. Paul Mastoridis will depart on 7 January 2025, CEO search now underway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paradigm Biopharmaceuticals Limited (PAR) ORDINARY FULLY PAID |
Health Care |
$131 |
Phase 3 Protocol Submission to US FDA
|
31 Oct 2024 8:20AM |
$0.200 |
$0.330 |
risen by
65%
|
|
PAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Paradigm has submitted the revised Phase 3 (PARA_OA_012) protocol to the FDA.
- The 30-day review period with the FDA starts on October 29, 2024.
- Enrollment for the trial is expected to begin in Q1 2025 at up to 10 Australian sites.
- The submission is a significant milestone for Paradigm in developing a treatment for knee osteoarthritis.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tigers Realm Coal Limited (TIG) ORDINARY FULLY PAID |
Materials |
$39 |
2024 September Quarterly Report
|
31 Oct 2024 8:20AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
TIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Tigers Realm Coal Limited is concluding the sale of its Russian subsidiaries.
- A Share Purchase Agreement was signed with APM-Invest for USD 49 million.
- Proceeds are intended to be used for returning capital to shareholders.
- One condition precedent related to presidential approval remains outstanding.
- Revenue from Russian subsidiaries is locked for APM-Invest's benefit.
- Any payments to the Sellers Group may trigger a Material Adverse Event.
- The SPA can be terminated if conditions are not met by October 9, 2024.
- Shareholders will be kept informed of the transaction's progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alvo Minerals Limited (ALV) ORDINARY FULLY PAID |
Materials |
$5 |
Amended Investor Presentation - IMARC Sydney
|
31 Oct 2024 8:20AM |
$0.090 |
$0.027 |
fallen by
70%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$51 |
Quarterly Activities & Cashflow Report
|
31 Oct 2024 8:20AM |
$0.125 |
$0.205 |
risen by
64%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- Island signed a binding Letter of Intent with BioCryst for the potential acquisition of antiviral molecule, galidesivir.
- The US FDA approved proposed amendment to the ISLA-101 Phase 2 clinical trial protocol.
- Mr Chris Ntoumenopoulos appointed Non-Executive Director.
- Post quarter, Island commenced its Phase 2a/b PROTECT clinical trial.
- Island secured A$3.5m in new funding.
- Island closed the quarter with a cash position of $0.72 million.
- All subjects have been dosed and exposed to the challenge virus in the Phase 2a trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Quickstep Holdings Limited (QHL) ORDINARY FULLY PAID |
Industrials |
- |
Annual Report to shareholders
|
31 Oct 2024 8:20AM |
$0.220 |
$0.575 |
risen by
161.36%
|
|
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$395 |
Update - Notification of buy-back - KGN
|
31 Oct 2024 8:20AM |
$4.720 |
$3.980 |
fallen by
15.68%
|
|
| Mach7 Technologies Limited (M7T) ORDINARY FULLY PAID |
Health Care |
$88 |
Appendix 4G and Corporate Governance Statement
|
31 Oct 2024 8:20AM |
$0.505 |
$0.375 |
fallen by
25.74%
|
|
| Quickstep Holdings Limited (QHL) ORDINARY FULLY PAID |
Industrials |
- |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Oct 2024 8:20AM |
$0.220 |
$0.575 |
risen by
161.36%
|
|
QHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations is $20.8 million, down 14% from FY24.
- EBITDA from continuing operations increased to $2.99 million, a 78% rise year-on-year.
- The Structures business underwent major restructuring to enhance efficiencies and profitability.
- The company is exiting its Services business due to declining orders.
- Net operating cash flows for Q1 were ($4.19 million), impacted by one-off restructuring costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Archer Materials Limited (AXE) ORDINARY FULLY PAID |
Information Technology |
$71 |
Invitation to attend presentation
|
31 Oct 2024 8:19AM |
$0.255 |
$0.280 |
risen by
9.80%
|
|
| Champion Iron Limited (CIA) ORDINARY FULLY PAID |
Materials |
$2,218 |
FY2025 Appendix 4D
|
31 Oct 2024 8:19AM |
$5.890 |
$4.160 |
fallen by
29.37%
|
|
CIA - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 19% to C$818,064.
- Net profit attributable to members rose by 23% to C$101,164.
- Dividends declared at C$0.10 per share.
- Net tangible assets per share improved to C$2.78.
- Review of financial statements conducted by Ernst & Young.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Whitefield Industrials Limited (WHF) ORDINARY FULLY PAID |
Financials |
$700 |
Update - Notification of buy-back - WHFPB
|
31 Oct 2024 8:19AM |
$5.610 |
$5.810 |
risen by
3.57%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
